These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 18626123

  • 21. Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users.
    Wood E, Kerr T, Palepu A, Zhang R, Strathdee SA, Tyndall MW, Montaner JS, Hogg RS.
    J Infect; 2006 Apr; 52(4):233-6. PubMed ID: 16169594
    [Abstract] [Full Text] [Related]

  • 22. Highly active antiretroviral therapy for injection drug users: physician-recommended strategies for enhanced adherence.
    Vassilev ZP, Hagan H.
    Antivir Ther; 2004 Jun; 9(3):461. PubMed ID: 15259910
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JS.
    JAMA; 2008 Aug 06; 300(5):550-4. PubMed ID: 18677027
    [Abstract] [Full Text] [Related]

  • 25. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.
    AIDS; 2008 Nov 12; 22(17):2371-80. PubMed ID: 18981777
    [Abstract] [Full Text] [Related]

  • 26. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
    Spire B, Lucas GM, Carrieri MP.
    Int J Drug Policy; 2007 Aug 12; 18(4):262-70. PubMed ID: 17689374
    [Abstract] [Full Text] [Related]

  • 27. A review of barriers and facilitators of HIV treatment among injection drug users.
    Wood E, Kerr T, Tyndall MW, Montaner JS.
    AIDS; 2008 Jul 11; 22(11):1247-56. PubMed ID: 18580603
    [Abstract] [Full Text] [Related]

  • 28. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
    Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M.
    Addiction; 2006 Mar 11; 101(3):433-40. PubMed ID: 16499516
    [Abstract] [Full Text] [Related]

  • 29. Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users.
    Wood E, Li K, Miller CL, Hogg RS, Montaner JS, Schechter MT, Kerr T.
    Int J Epidemiol; 2005 Feb 11; 34(1):152-8. PubMed ID: 15561747
    [Abstract] [Full Text] [Related]

  • 30. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.
    J Infect Dis; 2004 Sep 15; 190(6):1046-54. PubMed ID: 15319852
    [Abstract] [Full Text] [Related]

  • 31. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union.
    Wolfe D.
    Int J Drug Policy; 2007 Aug 15; 18(4):246-54. PubMed ID: 17689372
    [Abstract] [Full Text] [Related]

  • 32. Directly observed antiretroviral therapy for injection drug users with HIV infection.
    Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F.
    AIDS Read; 2002 Jul 15; 12(7):305-7, 312-6. PubMed ID: 12161852
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response.
    Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D, French Hospital Database on HIV.
    HIV Med; 2006 Nov 15; 7(8):520-9. PubMed ID: 17105511
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of the consistency of refills for antiretroviral medications in two hospitals in the state of Rio de Janeiro, Brazil.
    Seguy N, Diaz T, Campos DP, Veloso VG, Grinsztejin B, Teixeira L, Pillotto JH.
    AIDS Care; 2007 May 15; 19(5):617-25. PubMed ID: 17505922
    [Abstract] [Full Text] [Related]

  • 36. Adherence to HAART among patients with HIV: breakthroughs and barriers.
    Ickovics JR, Meade CS.
    AIDS Care; 2002 Jun 15; 14(3):309-18. PubMed ID: 12042076
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.
    Krüsi A, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg R, Montaner J, Wood E.
    Antivir Ther; 2010 Jun 15; 15(5):789-96. PubMed ID: 20710061
    [Abstract] [Full Text] [Related]

  • 39. Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam.
    Lambers FA, Stolte IG, van den Berg CH, Coutinho RA, Prins M.
    Int J Drug Policy; 2011 May 15; 22(3):210-8. PubMed ID: 21392958
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.